In less than one week, there has been a three per cent rise in casualties, as more 2,267 people have been struck with the disease, according to official WHO figures.
Metastatic cancer is responsible for the vast majority of cancer deaths, but our limited understanding of how metastasis begins makes finding ways to stop it hugely challenging. A new study may provide some insight, however.
Alterations in gut bacteria at a young age could help to trigger and progress multiple sclerosis in people who are genetically predisposed to the autoimmune disease.
People with depression and social anxiety have some common and specific structural abnormalities in their brains that can be spotted in imaging scans.
More connected medical devices are coming online every day, reshaping the way that healthcare networks are designed, used and secured.
Researchers at Stanford University School of Medicine with the National Cancer Institute (NCI) have identified another cancer-surface molecule, CD22, and begun trials on B-cell acute lymphoblastic leukemia (ALL) patients using an immuno-oncology approach similar to CAR-T. In the Phase I trial, 15 of the 21 patients who had previously relapsed or did not respond to anti-CD19 CAR-T, were treated with an anti-CD22 CAR-T therapy. Ten of the 15 patients had already received treatment for CD19-targeted treatment.
The U.S. Food and Drug Administration(FDA) today approved Juluca, the first complete treatment regimen containing only two drugs to treat certain adults with human immunodeficiency virus type 1 (HIV-1) instead of three or more drugs included in standard HIV treatment.
Encouraged by evidence of the impact that its diabetes drug semaglutide can have on obesity, with patients shedding an average of 16% of their weight in a mid-stage study, top researchers at Novo Nordisk today unveiled an ambitious late-stage strategy to make their mark in a tough, but potentially blockbuster market.
NHS England says it is planning to accelerate the NHS’ national research strategy, “cutting bureaucracy and speeding up access to new and innovative treatments”.
Twice on Thursday, Genentech, scored two approvals from the U.S. Food and Drug Administration(FDA) – a new medicine for hemophilia and an expansion for its cancer drug Gazyva.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.